<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2680872-A2" country="EP" doc-number="2680872" kind="A2" date="20140108" family-id="46758515" file-reference-id="317508" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587416" ucid="EP-2680872-A2"><document-id><country>EP</country><doc-number>2680872</doc-number><kind>A2</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12751964-A" is-representative="NO"><document-id mxw-id="PAPP154849608" load-source="docdb" format="epo"><country>EP</country><doc-number>12751964</doc-number><kind>A</kind><date>20120302</date><lang>EN</lang></document-id><document-id mxw-id="PAPP196210827" load-source="docdb" format="original"><country>EP</country><doc-number>12751964.3</doc-number><date>20120302</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140548112" ucid="US-201161448446-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161448446</doc-number><kind>P</kind><date>20110302</date></document-id></priority-claim><priority-claim mxw-id="PPC140552828" ucid="US-2012027480-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012027480</doc-number><kind>W</kind><date>20120302</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL2122913362" load-source="docdb">A61K  38/08        20060101AFI20141001BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2122915598" load-source="docdb">C07K   7/00        20060101ALI20141001BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2122916768" load-source="docdb">A61K  38/10        20060101ALI20141001BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2122918063" load-source="docdb">A61P  29/00        20060101ALI20141001BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2122919365" load-source="docdb">A61P   9/10        20060101ALI20141001BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2122922165" load-source="docdb">A61K  38/21        20060101ALI20141001BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2122923287" load-source="docdb">A61P  31/06        20060101ALI20141001BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1651130648" load-source="docdb" scheme="CPC">Y02A  50/411       20180101 LA20180409BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1651130649" load-source="docdb" scheme="CPC">Y02A  50/401       20180101 LA20180409BHEP        </classification-cpc><classification-cpc mxw-id="PCL2081248662" load-source="docdb" scheme="CPC">A61K  38/08        20130101 FI20140531BHEP        </classification-cpc><classification-cpc mxw-id="PCL2081249539" load-source="docdb" scheme="CPC">A61K  38/217       20130101 LI20140531BHEP        </classification-cpc><classification-cpc mxw-id="PCL2081253321" load-source="docdb" scheme="CPC">A61K  38/10        20130101 LI20140529BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132366881" lang="DE" load-source="patent-office">ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG INTRAZELLULÄRER SCHÄDEN</invention-title><invention-title mxw-id="PT132366882" lang="EN" load-source="patent-office">COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE</invention-title><invention-title mxw-id="PT132366883" lang="FR" load-source="patent-office">COMPOSITIONS ET PROCÉDÉS POUR TRAITER DES LÉSIONS INTRACELLULAIRES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919544750" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BIOINCEPT LLC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919524518" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BIOINCEPT LLC</last-name></addressbook></applicant><applicant mxw-id="PPAR919016651" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Bioincept LLC</last-name><iid>101260323</iid><address><street>1697 Lark Lane</street><city>Cherry Hill, NJ 08003</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919534901" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BARNEA EYTAN R</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919539811" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BARNEA, EYTAN R.</last-name></addressbook></inventor><inventor mxw-id="PPAR919009422" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BARNEA, EYTAN R.</last-name><address><street>1697 Lark Lane</street><city>Cherry Hill, New Jersey 08003</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919015709" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Fyfe, Fiona Allison Watson</last-name><iid>101205338</iid><address><street>Murgitroyd &amp; Company Scotland House 165-169 Scotland Street</street><city>Glasgow G5 8PL</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012027480-W"><document-id><country>US</country><doc-number>2012027480</doc-number><kind>W</kind><date>20120302</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012119072-A2"><document-id><country>WO</country><doc-number>2012119072</doc-number><kind>A2</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549787429" load-source="docdb">AL</country><country mxw-id="DS549773155" load-source="docdb">AT</country><country mxw-id="DS549787431" load-source="docdb">BE</country><country mxw-id="DS549855682" load-source="docdb">BG</country><country mxw-id="DS549857556" load-source="docdb">CH</country><country mxw-id="DS549919536" load-source="docdb">CY</country><country mxw-id="DS549773156" load-source="docdb">CZ</country><country mxw-id="DS549787432" load-source="docdb">DE</country><country mxw-id="DS549919537" load-source="docdb">DK</country><country mxw-id="DS549919538" load-source="docdb">EE</country><country mxw-id="DS549857425" load-source="docdb">ES</country><country mxw-id="DS549855683" load-source="docdb">FI</country><country mxw-id="DS549855684" load-source="docdb">FR</country><country mxw-id="DS549787437" load-source="docdb">GB</country><country mxw-id="DS549919539" load-source="docdb">GR</country><country mxw-id="DS549787438" load-source="docdb">HR</country><country mxw-id="DS549773165" load-source="docdb">HU</country><country mxw-id="DS549857557" load-source="docdb">IE</country><country mxw-id="DS549787439" load-source="docdb">IS</country><country mxw-id="DS549855685" load-source="docdb">IT</country><country mxw-id="DS549919540" load-source="docdb">LI</country><country mxw-id="DS549875287" load-source="docdb">LT</country><country mxw-id="DS549773166" load-source="docdb">LU</country><country mxw-id="DS549875288" load-source="docdb">LV</country><country mxw-id="DS549875289" load-source="docdb">MC</country><country mxw-id="DS549772855" load-source="docdb">MK</country><country mxw-id="DS549772856" load-source="docdb">MT</country><country mxw-id="DS549787440" load-source="docdb">NL</country><country mxw-id="DS549855686" load-source="docdb">NO</country><country mxw-id="DS549875295" load-source="docdb">PL</country><country mxw-id="DS549857562" load-source="docdb">PT</country><country mxw-id="DS549787449" load-source="docdb">RO</country><country mxw-id="DS549857563" load-source="docdb">RS</country><country mxw-id="DS549875296" load-source="docdb">SE</country><country mxw-id="DS549857564" load-source="docdb">SI</country><country mxw-id="DS549855687" load-source="docdb">SK</country><country mxw-id="DS549875297" load-source="docdb">SM</country><country mxw-id="DS549919541" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99830074" ref-ucid="WO-2012119072-A2" lang="EN" load-source="patent-office"><p num="0000">Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as<i> Listeria monocytogenes</i> infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.</p></abstract><abstract mxw-id="PA100326902" ref-ucid="WO-2012119072-A2" lang="EN" source="national office" load-source="docdb"><p>Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.</p></abstract><abstract mxw-id="PA99830075" ref-ucid="WO-2012119072-A2" lang="FR" load-source="patent-office"><p num="0000">Un facteur de préimplantation (PIF) peut être utilisé pour traiter des lésions intracellulaires. Dans ses modes de réalisation, la présente invention se rapporte à un procédé adapté pour traiter des lésions intracellulaires. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin. Dans certains de ses modes de réalisation, l'invention se rapporte à des procédés adaptés pour augmenter la sécrétion de cytokine en réponse à des lésions intracellulaires. Les procédés selon l'invention consistent à administrer un facteur PIF à un sujet qui en a besoin. Les lésions intracellulaires peuvent être un résultat d'une maladie telle qu'une infection par des<i> Listeria monocytogenes</i>, le paludisme, la maladie de Lyme, une maladie cardiovasculaire, un ulcère gastro-duodénal, une athérosclérose, une péritonite ou la tuberculose. Dans certains de ses modes de réalisation, l'invention se rapporte à un procédé adapté pour traiter la tuberculose. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin. Dans certains de ses modes de réalisation, l'invention se rapporte à un procédé adapté pour traiter une athérosclérose. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin. Dans certains de ses modes de réalisation, l'invention se rapporte à un procédé adapté pour traiter une péritonite. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin.</p></abstract><abstract mxw-id="PA100326903" ref-ucid="WO-2012119072-A2" lang="FR" source="national office" load-source="docdb"><p>Un facteur de préimplantation (PIF) peut être utilisé pour traiter des lésions intracellulaires. Dans ses modes de réalisation, la présente invention se rapporte à un procédé adapté pour traiter des lésions intracellulaires. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin. Dans certains de ses modes de réalisation, l'invention se rapporte à des procédés adaptés pour augmenter la sécrétion de cytokine en réponse à des lésions intracellulaires. Les procédés selon l'invention consistent à administrer un facteur PIF à un sujet qui en a besoin. Les lésions intracellulaires peuvent être un résultat d'une maladie telle qu'une infection par des Listeria monocytogenes, le paludisme, la maladie de Lyme, une maladie cardiovasculaire, un ulcère gastro-duodénal, une athérosclérose, une péritonite ou la tuberculose. Dans certains de ses modes de réalisation, l'invention se rapporte à un procédé adapté pour traiter la tuberculose. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin. Dans certains de ses modes de réalisation, l'invention se rapporte à un procédé adapté pour traiter une athérosclérose. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin. Dans certains de ses modes de réalisation, l'invention se rapporte à un procédé adapté pour traiter une péritonite. Le procédé selon l'invention consiste à administrer un facteur PIF à un sujet qui en a besoin.</p></abstract><description mxw-id="PDES51232067" ref-ucid="WO-2012119072-A2" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> TITLE: COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE</p><p id="p0002" num="0002">RELATED APPLICATION </p><p id="p0003" num="0003">[0001] This application claims priority under 35 U.S.C § 1 19 to U.S. Provisional Patent Application No. 61/448,446, filed March 2, 2011, entitled "COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE," the disclosure of which is incorporated herein by reference. </p><p id="p0004" num="0004">SUMMARY </p><p id="p0005" num="0005">[0002] Embodiments herein are directed to pre-implantation factor (PIF) for use in the treatment of intracellular damage. Embodiments are directed to a method of treating intracellular damage comprising administering a PIF peptide to a subject in need thereof. In some embodiments, the PIF peptide administered is in a therapeutically effective amount. In some embodiments, the intracellular damage may be the result of a disease. In some embodiments, the disease is caused by an intracellular bacterium. In some embodiments, the intracellular bacterium may be selected from Listeria monocytogenes, Mycobacterium tuberculosis, Heliobacter pylori, Borrelia burgdorferi sensu stricto, Borelia afzelii, and Borrelia garinii. In further embodiments, the disease may be selected from Listeria, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis and tuberculosis. In some embodiments, the method of treating intracellular damage further comprises administering a potassium channel inhibitor. In some embodiments, the potassium channel inhibitor may be a Kvl.3 inhibitor. In some embodiments, the potassium channel inhibitor may be IFNy. </p><p id="p0006" num="0006"> [0003] Embodiments are directed to a method of treating tuberculosis comprising administering a PIF peptide. In some embodiments, PIF may neutralize local immune suppression induced by Mycobacterium tuberculosis (Mtb)-infected macrophages and/or increase host's immune response against Mtb infection. In further embodiments, PIF may prevent intracellular damage caused by tuberculosis. In some embodiments, a subject is diagnosed with tuberculosis. In some embodiments, a subject is at risk for tuberculosis. In some embodiments, the method may further comprise administering PIF in combination with other anti-tuberculosis agents. 
<!-- EPO <DP n="3"/>-->
 [0004] Embodiments are directed to a method of decreasing dissemination of tuberculosis bacteria comprises administering PIF to a subject in need thereof. In some embodiments, the PIF peptide administered is in a therapeutically effective amount. In some embodiments, the method may further comprise administering PIF in combination with other anti-tuberculosis agents. </p><p id="p0007" num="0007"> [0005] Embodiments are directed to a method of protecting against inflammation in intracellular damage comprising administering a PIF peptide to a subject in need thereof. Some embodiments describe a method of increasing cytokine secretion in response to intracellular damage comprising administering a PIF peptide to a subject in need thereof. In some embodiments, the PIF administered is in a therapeutically effective amount. In some embodiments, the intracellular damage may be the result of a disease. In some embodiments, the disease is caused by an intracellular bacterium. In further embodiments, the disease may be selected from a Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, diabetes, duodenal peptic ulcer, atherosclerosis and tuberculosis. In some embodiments, the method of protecting against inflammation in intracellular damage further comprises administering a potassium channel inhibitor. In some embodiments, the potassium channel inhibitor may be a Kvl.3 inhibitor. In some embodiments, the potassium channel inhibitor may be IFNy. </p><p id="p0008" num="0008"> [0006] Embodiments are directed to a method of modulating a potassium channel comprising administering a PIF peptide. In some embodiments, the potassium channel is Kvl.3. In some embodiments, modulating comprises blocking the activity of the potassium channel. In some embodiments, the PIF peptide modulates the potassium channel by binding to the channel. In some embodiments, the PIF administered is in a therapeutically effective amount. </p><p id="p0009" num="0009"> [0007] Embodiments are directed to a method of treating atherosclerosis in a subject comprising administering a PIF peptide. In some embodiments, a therapeutically effective amount of PIF is administered. In some embodiments, a subject is diagnosed with atherosclerosis. In some embodiments, the subject is at risk for atherosclerosis. In some embodiments, the method may further comprise administering PIF in combination with other anti-atherosclerotic agents. </p><p id="p0010" num="0010"> [0008] In some embodiments, PIF may treat atherosclerosis by reducing plaque in the aortic root. In some embodiments, PIF may treat atherosclerosis by reducing plaque in the aortic arch. In some embodiments, PIF may treat atherosclerosis by reducing a monocyte 
<!-- EPO <DP n="4"/>-->
 protein in the aortic arch. In further embodiments, the monocyte protein may be selected from vascular cell adhesion molecules (VCAM-1), monocyte chemotactic proteins (MCP-1) and clusters of differentiation (CD68). In some embodiments, PIF may treat atherosclerosis by reducing a monocyte protein in the aortic root. In further embodiments, the monocyte protein may be selected from vascular cell adhesion molecules (VCAM-1), monocyte chemotactic proteins (MCP-1) and clusters of differentiation (CD68). In some embodiments, PIF may treat atherosclerosis by reducing lipids in the aortic root. In some embodiments, PIF may treat atherosclerosis by reducing a cytokine in THP-1 cells. In further embodiments, the cytokine may be selected from interleukein 12, subunit beta (IL-12b) and interferon gamma (IFN-γ). The effect on plaque reduction on the aorta is direct without affecting circulating lipids. </p><p id="p0011" num="0011"> [0009] Embodiments are directed to a method of treating peritonitis in a subject comprising administering a PIF peptide. In some embodiments, a therapeutically effective amount of PIF is administered. In some embodiments, a subject is diagnosed with peritonitis. In some embodiments, the subject is at risk for peritonitis. In some embodiments, the method may further comprise administering PIF in combination with other anti-peritonitis agents. </p><p id="p0012" num="0012"> [00101 In embodiments, the PIF peptide may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; or SEQ ID NO: 8. In embodiments, the PIF peptide may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4. In embodiments, the PIF peptide may be selected from SEQ ID NO: 1; SEQ ID NO: 2; and SEQ ID NO: 3. </p><p id="p0013" num="0013">BRIEF DESCRIPTION OF THE FIGURES </p><p id="p0014" num="0014">[0011] The file of this patent contains at least one photograph or drawing executed in color. Copies of this patent with color drawing(s) or photograph(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee. </p><p id="p0015" num="0015"> [0012] For a fuller understanding of the nature and advantages of the present invention, reference should be had to the following detailed description taken in connection with the accompanying drawings, in which: </p><p id="p0016" num="0016"> [0013] FIG. 1 illustrates (A) a magnified immune cell showing FITC-PIF binding (fluorescent microscopy) at x2000 magnification; the uptake appears to be intracellular. (B) Minimal FITC-PIF binding to naive PBMCs (phase-contrast microscopy) x40 magnification. (C) FITC-PIF binds all unstimulated CD 14+ cells (upper right panel); minimal binding to 
<!-- EPO <DP n="5"/>-->
 unstimulated CD4+ and CD8+ cells (lower left and right panels). (D) unstained negative control and (E) test human blood underwent RBC lysis procedure and was incubated with PIF-FITC (luM) or PBS for 15 mins. The results indicated the PIF-FITC binds mainly to granulocyte population based on FSC/SSC. (F) Human whole blood was incubated with PIF- FITC + CD66b (top graphs) or CD 14 (bottom graphs). Results indicated the PIF-FITC binds strongly to CD66b positive granulocytes follow by CD14 positive monocytes. (G) lOOuM PIF-FITC (50ul) (top row) was injected to 25 g C57/BL6 mice through the jugular vein. The mice were culled 5 minutes after injection. Blood was collected through the inferior vena cava in a heparin tube. Red blood cells were lysed by a lysis buffer. Cell was resuspended in FACS buffer and stained for CD14-PE (middle row) and CD45-APC (bottom row). The results indicated the binding of PIF-FITC to granulocytes (P3); these granulocyte may have CD14 and CD45 markers. (FT) Cell types that interact with PIF. Mouse blood and bone marrow cells were stained for one hour with PIF-FITC conjugate and markers for immune cell sub-populations. FACS analysis revealed that PIF preferably interacts with CDl lb+ Monocytes. (I) Dose-dependent binding of FITC-PIF to CD 14+ cells, coupled with incomplete saturation of CD8+, CD4+, CD56+ (NK cells) and CD 19+ cells even at 10-fold higher concentrations of FITC-PIF. Results are mean values of 4-10 samples per cell lineage. </p><p id="p0017" num="0017"> [0014] FIG. 2 illustrates (A) that PIF reduces allogenic lymphocyte proliferation in a dose dependent manner in MLR analysis. Mouse splenocytes were used for mixed Lymphocytes Reaction (MLR). Balb/c cells were cultured in the presence of irradiated C57/B1 cells for 4 days. Different concentrations of PIF were added to the culture media. Cell proliferation was tested by H3 Tymidine uptake assay. PIF was found to reduce cells proliferation in a dose dependent manner. The differences between the positive control (Pos.), 150nM and 200nM PIF are significant (Mann- Whitney: P&lt;0.03). One representative experiment is shown out of four performed. (B) PIF-treated CDl lb+ cells were found to inhibit T cell proliferation. Bone marrow derived Monocytes were grown in culture for 10 days in the presence of 200nM PIF and then co-cultured with T cells for 4 days. Anti-CD3 antibodies were added to the medium for T cell activation. Cell proliferation was tested by H3 Thymidine uptake. PIF-treated monocytes reduced proliferation but did not block it, which is likely because PIF's effect is modulatory and not inhibitory. (C) PIF up-regulates B7-H1 regulatory protein in CDl lb+ cells. Bone marrow derived Monocytes were grown in culture for 10 days in the presence or absence of 200nM PIF. At day 7, lOOng/ml IFN γ was added. After 10 days cells were analyzed by FACS analysis using anti-B7-Hl antibodies. 
<!-- EPO <DP n="6"/>-->
 (D) Murine macrophages were cultured with GM-CSF for 10 days. IFN-γ was added to the culture at day 7 for cell activation. When sPIF added to the culture at day 0 or 7, B7-H1 expression was significantly increased. This is relevant since B7-H1 is one of the newly defined inhibitory B7 family molecules. It is known that IFN gamma potently stimulates B7- Hl expression on APC. (E) PIF Reduced VCAM-1, IL-12b and IFNg in THP-1 cells. THP- 1 cells were incubated for 48 hours, then were stimulated with lOug/TGF-b and collected at 0, 1, 8, 12 and 24 hour time points. This showed gene regulation changes at certain time points. The 8 hour time point was selected to allow time for cell stimulation. The gene regulation comes quickly and the selected time point allows enough time for stimulation and not over/under. (F) PIF reduces Nos2 expression in vivo and NO secretion from RAW, mouse macrophage cell line, in vitro. These results were taken as part of Real-Time quantitative PCR analysis of inflammatory gene expression in the liver using "Mouse Inflammatory Response and Autoimmunity" array. cDNA samples were obtained from livers of normal mice or mice after semi-allogemc (allo.)/singenic (sin.) bone marrow transplantation, treated with PIF or PBS. The expression of Nos2 elevated in semi-allogenic BMT mice, 17 fold comparing with normal mice. PIF completely prevented this elevation. (G) RAW (Macrophage cell line) was cultured with 200nM PIF for different time periods. In the last 24 hours of the experiment, LPS was added to the culture for cell activation. Greiss reagent test was performed to detect NO secretion to the supernatant. PIF was found to reduce NO secretion from RAW. </p><p id="p0018" num="0018"> [0015] FIG. 3 (A) and (B) illustrate that mitogen stimulation enhances FITC-PIF binding to T and B cell populations. PBMC were cultured with PHA for 24 h. Binding of FITC-PIF to different PBMC populations was determined by two color flow cytometry. Binding was low (&lt;10% in unstimulated cells a, upper panel from left to right) CD4+, CD8+, NK, (CD56+) and B (CD 19+) cells. However, it led to a ~30-fold increase in binding to b (lower panel from left to right), CD4+, CD8+ and B (CD 19+) cells. Binding was unchanged for NK cells, even after a 72 hour incubation period. (C) through (F) illustrate that sPIF promotes T<sub>h</sub>2/TH1 cytokine bias in stimulated PBMCs. PBMCs were cultured with +/-sPIF 50nM +/- anti-CD3-mAb or 50 nM PIF scr+/- anti-CD3-mAb for 4-96 hours. (B) sPIF (50 nM); (C) PIFscr (50 nM); (D) sPIF (50 nM) + anti-CD3 mAb; (E) PIFscr + anti-CD3 mAb. sPIF affected variably stimulated PBMCs individual cytokines secretion. In contrast, some cytokine secretion in naive PBMCs decreased (not shown). PIFscr affected only TNFa secretion (N=5). Cytokine secretion determined by Luminex 10-plex. (F) PIF promotes anti- 
<!-- EPO <DP n="7"/>-->
 CD3/CD28 induced TH2 and TH1 cytokines secretion. PBMCs were cultured in the presence of anti-CD3/anti-CD28-Mab for 24-48 hours. PIF increased both types of cytokines following TCR stimulation. PIF alone had no significant promoting effect on cytokine secretion, representative of three different experiments. The effect on PBMCs at 48 hours was less pronounced (data not shown). At the end of experiment mRNA was extracted and global gene expression was analyzed by using an Affymetrix chip. </p><p id="p0019" num="0019"> [0016] FIG. 4 illustrates (A) that IL-la was induced by Mtb and was then augmented by PIF and anti-Kvl.3. The response was lost in the presence of IFN. (B) IL-lb was induced by Mtb and was then augmented by PIF and anti-Kvl.3. The response was lost in the presence of IFN. (C) (TNF)a was induced by Mtb and was then augmented by PIF and anti-Kvl.3. The response was lost in the presence of IFN. (D) MIP-lalpha was induced by Mtb and was then augmented by PIF and anti-Kvl .3. The response was lost in the presence of IFN. (E) KC was induced by Mtb and was then augmented by PIF and anti-Kvl.3. The response was lost in the presence of IFN. </p><p id="p0020" num="0020"> [0017] FIG. 5 illustrates (A) that MCP-1 (a chemokine) was induced by Mtb, which was augmented by PIF and a Kvl.3 inhibitor. Administration of IFNy stopped the response. Low sPIF doses increased MCP-1 (Monocyte chemo tactic protein- 1) secretion by isolated macrophages. The Kvl.3 inhibitor at lOOnM blocked sPIF effect. (B) IL-6 was induced by Mtb and this induction was augmented by PIF and reduced by anti-Kvl.3. Administration of IFN stopped the response. (C) IL-5 was induced by Mtb and this induction was augmented by PIF and reduced by anti-Kvl.3. Administration of IFN stopped the response. </p><p id="p0021" num="0021"> [0018] FIG. 6 illustrates that PIF inhibits MCP-1 induced monocyte migration in a mouse peritonitis model. 8-12 weeks old C57W6 mice were injected with PIF or scPIF (0.3nmol/g i.p.) or PBS as vehicle control. Peritonitis was induced by injecting 3ml 4% thioglycolate i.p. and after 20 hours, the mice were anaesthetized and the peritoneal cavity was flushed with 5ml sterile PBS. Subsequently, monocytes/macrophages were quantified with F4/80 and CD1 lb in flow cytometry. PIF (ΙμΜ &amp; 10μΜ) significantly reduced MCP-1 induced transmigration of THP-1 cells in an in vitro transwell migration assay (*p&lt;0.01). PIF inhibits leukocyte adhesion and rolling in mesenteric venules in intravital microscopy using the peritonitis model as described in (B) and cell staining with rhodamine. </p><p id="p0022" num="0022"> [0019] FIG. 7 illustrates that PIF reduces atherosclerotic plaque area in the (A) aortic root and (B) the aortic arch. Aortic root and arch sections were stained with HE. The mean atherosclerotic area (μηι2) ± SEM was quantified. PIF 0. lmg/kg/day treatment 
<!-- EPO <DP n="8"/>-->
 significantly reduced the plaque area in the aortic root by 30% compared to the PBS control (**p=0.0008). A greater reduction of 46% was evident in PIF lmg/kg/day compared to PBS (****p&lt;0.0001). The higher dose of PIF also statistically significantly reduced plaque area compared to both doses of scrPIF (****p&lt;0.0001). PIF lmg/kg/day treatment significantly reduced the plaque area of the aortic arch by 43% compared to the PBS control (**p&lt;0.002). A reduction was again also evident between PIF lmg/kg/day and both doses of scrPIF (***p=0.0005, **** p&lt; 0.0001 respectively). </p><p id="p0023" num="0023"> [0020] FIG. 8 (A) through (F) illustrate that PIF reduces VCAM-1, MCP-1 and CD68 in the aortic root and arch of ApoE-/- mice fed with high fat diet (n=8 each, mean and SEM, *ρ&lt;0·05, **p&lt;0.01, ***p&lt;0.001, ****ρ&lt;0·0001). </p><p id="p0024" num="0024"> [0021] FIG. 9 (A) through (D) illustrate that PIF but not scrPIF reduces Oil Red O (ORO) staining in the aortic arch and root. ORO histology was employed to identify lipids in the mouse atherosclerotic plaque. Lipids were quantified by red signal intensity percentage area of plaque ± SEM. (A) signifies PIF lmg/kg/day treatment causes a significant reduction in lipids compared to ScPIF lmg/kg/day in the aortic root ((n=8, **p&lt;0.01, ****p = &lt; 0.0001). To confirm the reduction in lipids and foam cells were due to PIF's actions on the atherosclerotic lesion and not fat levels as a whole, Cobas was used to determine the cholesterol levels using mouse plasma from different treatment groups. All animals still had very high cholesterol levels and to obtain a reading, the plasma was diluted to 1: 10. After analysis, no statistical difference was seen between any group using one way ANOVA paired with Tukey's Multiple Comparison Test. </p><p id="p0025" num="0025"> [0022] FIG. 10 illustrates that PIF reduces: (A) CD68 in the aortic root (** p = 0.0017) and the aortic arch (** p = 0.0035), and (B) lipids in the aortic root (**** p = &lt; 0.0001) and the aortic arch (** p = 0.0093). </p><p id="p0026" num="0026"> [0023] FIG. 11 illustrates that PIF does not affect circulating lipids, and no change in plasma cholesterol is noted. A COBAS analyzer was used to determine the cholesterol levels by using mouse plasma from the various treatment groups. All animals still had very high cholesterol levels, and to obtain a reading the plasma needed to be diluted to 1 : 10. No statistical difference was seen between any group using one way ANOVA paired with Tukey's Multiple Comparison Test. This confirmed that the reduction in lipids and foam cells were due to PIF's actions on the atherosclerotic lesion and not on the fat levels as a whole. 
<!-- EPO <DP n="9"/>-->
 DETAILED DESCRIPTION </p><p id="p0027" num="0027">[0024] Before the present compositions and methods are described, it is to be understood that this invention is not limited to the particular processes, compositions, or methodologies described, as these may vary. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. </p><p id="p0028" num="0028"> [0025] It must also be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to a "peptide" is a reference to one or more peptides and equivalents thereof known to those skilled in the art, and so forth. </p><p id="p0029" num="0029"> [0026] As used herein, the term "about" means plus or minus 10% of the numerical value of the number with which it is being used. Therefore, about 50% means in the range of 45%-55%. </p><p id="p0030" num="0030"> [0027] "Administering" when used in conjunction with a therapeutic means to administer a therapeutic directly into or onto a target tissue or to administer a therapeutic to a patient whereby the therapeutic positively impacts the tissue to which it is targeted. Thus, as used herein, the term "administering", when used in conjunction with preimplantation factor (PIF), can include, but is not limited to, providing PIF into or onto the target tissue; providing PIF systemically to a patient by, e.g., intravenous injection whereby the therapeutic reaches the target tissue; providing PIF in the form of the encoding sequence thereof to the target tissue (e.g., by so-called gene-therapy techniques). "Administering" a composition may be accomplished by parenteral, oral or topical administration, or by such methods in combination with other known techniques. Such combination techniques include heating, radiation and ultrasound. 
<!-- EPO <DP n="10"/>-->
 [0028] The term "animal" or "patient" or "subject" as used herein includes, but is not limited to, humans and non-human vertebrates such as wild, domestic and farm animals. Preferably, the term "animal" or "patient" or "subject" refers to humans. </p><p id="p0031" num="0031"> [0029] The term "improves" is used to convey that the present invention changes either the appearance, form, characteristics and/or the physical attributes of the tissue to which it is being provided, applied or administered. The change in form may be demonstrated by any of the following alone or in combination: treatment of an infection/inflammation as the result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis and tuberculosis; alleviation of symptoms of a disease; increase in granuloma formation; increase in cytokine secretion; increase in secretion of perforin and granulysin; modulation of disease-infected phagocytes' cytokine/chemokine secretion; and decrease in dissemination of bacteria. </p><p id="p0032" num="0032"> [0030] The term "inhibiting" includes the administration of a compound of the present invention to prevent the onset of the symptoms, alleviating the symptoms, or eliminating the disease, condition or disorder. </p><p id="p0033" num="0033"> [0031] By "pharmaceutically acceptable", it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. </p><p id="p0034" num="0034"> [0032] As used herein, the term "therapeutic" means an agent utilized to treat, combat, ameliorate, prevent or improve an unwanted condition or disease of a patient. In part, embodiments of the present invention are directed to methods of treating tuberculosis. </p><p id="p0035" num="0035"> [0033] A "therapeutically effective amount" or "effective amount" of a composition is a predetermined amount calculated to achieve the desired effect, i.e., to reduce, inhibit or improve the symptoms of the disease or condition. The activity contemplated by the present methods includes both medical therapeutic and/or prophylactic treatment, as appropriate. The specific dose of a compound administered according to this invention to obtain therapeutic and/or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, and the condition being treated. The compounds are effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.001 to 10 mg/kg, more usually in the range of from 0.01 to 1 mg/kg. However, it will be understood that the effective amount administered will be determined by the physician in 
<!-- EPO <DP n="11"/>-->
 the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. A therapeutically effective amount of compound of embodiments of this invention is typically an amount such that when it is administered in a physiologically tolerable excipient composition, it is sufficient to achieve an effective systemic concentration or local concentration in the tissue. </p><p id="p0036" num="0036"> [0034] The terms "treat," "treated," or "treating" as used herein refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. </p><p id="p0037" num="0037"> [0035] Listeria monocytogenes, a Gram-positive facultative intracellular bacterium, survives and replicates in the cytoplasm of phagocytes and hepatocytes following escape from the phagosome. The innate immune response to Listeria infection is a complicated process involving not only many cell types, including macrophages, chemokines (MlP)-la and KC, natural killer (NK) cells and neutrophils, but also nitrogen intermediates and cytokines such as tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-12, interferon (INF)-c, and the more recently identified early T lymphocyte activation (Eta)-l . It is widely believed that TNF-a and nitric oxide (NO), an end product of inducible nitric oxide synthase (iNOS) produced by macrophages and a newly identified TNF/iNOS-producing dendritic cell (Tip-DC), may be key effector molecules responsible for the protection of the host from early Listeria infection in conjunction with INF-c, which is mainly secreted by NK cells. Numerous studies also indicate that the CD8+ T-cell immune response may play a prominent role in the complete clearance of Listeria monocytogenes in infected mice through IFN-c- mediated mechanisms whereby escape of L. monocytogenes from the phagosome is inhibited 
<!-- EPO <DP n="12"/>-->
 and macrophages are activated. Furthermore, CD4+ T cells may also be engaged in antilisterial resistance by providing CD8+ T cells with B7-l/B7-2-mediated costimulation by DCs through the CD40-CD40L interaction, and by polarizing the immune response towards a T helper type 1 (Thl) pathway. Specifically, B7-1 and B7-2 costimulatory molecules may be necessary for the production of IFN-c and IL-2 from Thl CD4+ T cells during Listeria infection. B7-H1 (also known as CD274 and PD-L1) is a member of the B7 family that positively or negatively controls Tcell receptor (TCR)-mediated signaling. The findings of a series of in vivo studies using either the antagonistic anti-B7-Hl antibody or gene knockout mice support the coinhibitory role of endogenous B7-H1 ; for example, in vivo blockade of B7-H1 with antagonistic monoclonal antibody (mAb) may activate effector T cells, leading to an increase in the incidence of autoimmune diabetes in non-obese diabetic (NOD) mice, hapten-induced contact hypersensitivity in normal mice, and susceptibility to experimental autoimmune encephalomyelitis in B7-H1 knockout mice. However, the findings that transgenic expression of B7-H1 by b-islet cells induces spontaneous diabetes and accelerates the rejection of b-islet cells in allogeneic hosts, and that the antagonistic antibody to B7-H1 inhibits the pathogenesis of inflammatory bowel disease, suggest that B7-H1 plays a costimulatory role in T-cell immunity in vivo. While B7-H1 has been implicated in T-cell immunity in cancer progression, autoimmunity and graft rejection in many studies, there are few reports elucidating the role of endogenous B7-H1 in infection models. </p><p id="p0038" num="0038"> [0036] Tuberculosis (TB), caused by bacilli Mycobacterium tuberculosis (Mtb), is a serious and life threatening disease which infects about 8 million and kills 3 million people annually worldwide. Mtb invades and replicates within the endosomes of alveolar macrophages, altering their activity. Localized immune suppression within mononuclear cell granulomas develops following Mtb infection. Macrophages, T lymphocytes, B lymphocytes and fibroblasts are among the cells that aggregate to form a granuloma, with lymphocytes surrounding the infected macrophages. The granuloma functions not only to prevent dissemination of the mycobacteria, but also provides a local environment for communication of cells of the immune system. Within the granuloma, T lymphocytes secrete cytokines such as interferon (IFN)-gamma, which activates macrophages to destroy the bacteria with which they are infected. Cytotoxic T cells can also directly kill infected cells, by secreting perforin and granulysin. Importantly, Mtb may survive in granulomas by going into a latent state. </p><p id="p0039" num="0039"> [0037] Lyme disease, which is also known as Lyme borreliosis, is the most common tick-borne infectious disease in the northern hemisphere. Lyme disease is caused by 
<!-- EPO <DP n="13"/>-->
 at least three species of bacteria belonging to the genus Borrelia. The bacterium Borrelia burgdorferi sensu stricto causes most cases of Lyme disease in the United States, whereas Borrelia afzelii and Borrelia garinii cause most cases of Lyme disease in Europe. Borrelia is transmitted to humans by the bite of infected ticks belonging to a few species of the genus Ixodes ("hard ticks"). Early symptoms may include fever, headache, fatigue, depression, and a characteristic circular skin rash called erythema migrans (EM). Left untreated, later symptoms may involve the joints, heart, and central nervous system. </p><p id="p0040" num="0040"> [0038] Atherosclerosis, which is also known as arteriosclerotic vascular disease (ASVD), is a condition noted by vascular wall thickening. The thickening is generally a result of an accumulation of fatty materials such as cholesterol, which form hard structures called plaques. Recent clinical and experimental evidence indicates that inflammatory processes in the vascular wall are the decisive factor that accounts for the rate of lesion formation and clinical development in patients suffering from atherosclerosis. Evidence has further indicated that recruitment of monocytes to, as well as the retention of monocytes within, the atherosclerotic lesions contributes to the progression of plaque development. </p><p id="p0041" num="0041"> [0039] Mammalian pregnancy is a unique physiological event in which the maternal immune system interacts with the fetus in a very efficient manner, which is beneficial for both parties. Pregnancy is an immune paradox, displaying no graft vs. host or host vs. graft effect. Pregnancy is an immune-modulatory state which provides such desired effective immune protection (modulation without suppression). In it, vertical transmission of TB infection from mother/host to newborn/allograft is low, analogous to the protection observed against HIV and various immune disorders such as multiple sclerosis. Without wishing to be bound by theory, it is believed that activation of the host's immune system could be instrumental in the treatment of tuberculosis and embryo-specific protective compounds could have such a pivotal protective role against tuberculosis. Successfully transposing pregnancy's immune-modulatory effects to the non-pregnant immune state may result in a powerful, effective, nontoxic tool to control TB. Thus, having an agent that may act in synergy with anti-TB agents may represent a critical supportive element in the protection against this serious disease. </p><p id="p0042" num="0042"> [0040] A novel pre-implantation factor (PIF) is an early (two-cell stage) message from the embryo/allograft to mother/host. PIF creates immune tolerance and acceptance while playing an essential role in responding as needed to pathogen challenge. The synthetic analog of PIF (sPIF) replicates the native peptide's effect on activated peripheral blood 
<!-- EPO <DP n="14"/>-->
 mononuclear cell (PBMC) proliferation and cytokine secretion, acting through novel sites on PBMC and having an effect which is distinct from known immune-suppressive drugs. As used herein PIF or PIF peptide is a synethetic PIF peptide or an isolated, naturally occurring PIF peptide. PIF's protective effect occurs throughout viable pregnancy without affecting the host's basal immunity. sPIF mimics its physiologic counterpart, enhances activated immunity "per need" both to prevent and regress ongoing immune injury without interfering with basal immunity required for survival. Thus, PIF controls inflammation without broad immunosuppression. Localized immune suppression within mononuclear cell granulomas develops following Mtb infection. Accordingly, PIF may prove useful in treatment of TB. Therefore, it is believed that PIF may target the Kvl.3 potassium channel, an anti-TB target. </p><p id="p0043" num="0043"> [0041] While not wishing to be bound by theory, sPIF blocks activated PBMCs proliferation, creates a TH2/TH1 cytokine bias and promotes pro-tolerance while reducing pro-rejection genes. This is achieved by binding PIF to macrophages and in activated cells to T and B cells presumably acting through K+ (not Ca++) channels used by immune suppressive agents. Within the pregnant uterus, PIF accumulates within NK cells, which mitigates maternal hostility. Hence, embryo-secreted PIF modulates both peripheral and local immunity, creates a favorable environment for the embryo for implantation and facilitates trophoblast invasion, thus revealing an essential role of the peptide in promoting pregnancy. </p><p id="p0044" num="0044"> [0042] The observed biphasic binding and effect of PIF on immune cells provides interesting insights into pregnancy-related tolerance. The present study clearly has shown differences in PIF's effect on stimulated (challenged) and immune naive cells. The decrease noted in MLR, following exposure to sPIF, reflects a diminished alio- antigenic response. This may explain why donor embryos (allogenic) can successfully implant, and genetic similarity or same species breeding is not necessary. PIF necessarily maintains basal immunity required for survival, and aids in tolerance for self by blocking activated T cells proliferation that would harm the embryo. </p><p id="p0045" num="0045"> [0043] The differential effect of sPIF on naive or stimulated, or even co-stimulated PBMCs is also evident on cytokines. In the former circumstance, sPIF reduced proinflammatory TH1 response, while following stimulation of PMBCs, sPIF created a TH2 cytokine bias. Increased levels of TH1 and TH2 cytokines in pregnancy were recently reported. Decrease in IL-2 and (associated genes) a prime inducer of cytotoxic T cells proliferation and TNF-family member was noted in naive cells, while CCL7, a regulator of 
<!-- EPO <DP n="15"/>-->
 monocyte function, increased. In stimulated cells, since there is a need to respond to pathogens, potent TH1 cytokines (IFNy and TNFa) increased. The divergent effects on IL10 secretion and gene expression (decrease in naive and increase in activated cells) indicate that PIF prevents deleterious immune suppression under basal conditions while protecting against rejection when maternal immunity is under challenge. </p><p id="p0046" num="0046"> [0044] Global PMBCs gene expression data further corroborated PIF-induced differences between basal and challenged environments. In the former, pro-tolerant genes increased while those that promote embryo rejection were reduced. Remarkably, under co- stimulation, the anti-rejection genes had to be balanced by promoting defense mechanisms required to fight disease. Both naive and stimulated cells increased TGFBRII expression. TGFp binding inhibited T cells proliferation and prevented macrophage activation. sPIF increased FKBPl, the FK506 binding protein, involved in the calcineurin pathway critical for tolerance induction. Of interest, that the same gene was also up-regulated in human decidua following sPIF exposure. In stimulated cells, sPIF promoted tolerance by increasing IDO that degrades L-tryptophan induced by IFNy and cyclophylin B, a tolerance inducing molecule where cyclosporin binds. The increase noted in HLA-G3 expression mitigates immune cells attack on the embryo. On the other hand, facilitating maternal immune response sPIF increased two tyrosine kinases, LCK, which plays a key role in TCR- linked signal transduction pathways and Fyn, which is involved in control of cell growth. The reduction in CD31 reflects a decrease in neutrophil action, as does the decrease in CCR4, a pro-inflammatory chemokine. Overall, the gene data further substantiate dual comprehensive modulatory effects of PIF which result in balancing tolerance with supporting maternal immunity to combat disease. </p><p id="p0047" num="0047"> [0045] The differential FITC-sPIF binding profile to subsets of naive (CD 14+) or stimulated PBMC (T and B) is in line with the observed immune modulatory effects. Innate immunity is readily preserved to avoid attack on the embryo. The enhanced binding to T and B cells at high ligand concentrations and in activated PBMCs at low concentration reflect effective interaction with the adaptive arm of the immune system. PIF also binds to Treg (FoxP3+) activated T cells subtype while only a limited binding to NK+ cells observed under mitogen challenge reflecting target specificity. Thus, PIF binding properties further support the observed differences on innate and adaptive immunity. </p><p id="p0048" num="0048"> [0046] sPIF mechanism is unique, not exerted through calcium mobilization, binding to GPCR/Gq receptors seen with immune suppressive drugs (cyclosporine, FK506) 
<!-- EPO <DP n="16"/>-->
 since PIF has no effect alone or PBMC activated by PHA or PMA/Ionomycin. However PIF synergizes with anti-CD3 mAb to stimulate IL-2 a major product of calcineurin signaling, while also promoting FK506 binding protein up-regulation, suggesting a downstream involvement in this pathway. Recent data together with current study implicates K+ channels in the PIF-induced observed effects. PIF binds to Kvl .3 beta-channels that modulate the ion pore and gene expression data demonstrates modulation of K+ genes. </p><p id="p0049" num="0049"> [0047] Beyond peripheral immunity, local uterine immunity may also need to be controlled to achieve successful reproduction. Embryo-secreted PIF may be localized within granules of murine uNK cells at the maternal-fetal interface, possibly, targeting intra cellular binding sites. PIF, derived from the surrounding trophoblastic cells rapidly diffuse into uNK cells. Thus, PIF may down-regulate uNK cytotoxic functions or modulate cytokine secretion to support the conceptus' survival. At the point when direct embryo-maternal interaction takes place during implantation, PIF plays a significant role in concert with other pro- implantation elements. </p><p id="p0050" num="0050"> [0048] PIF may have an essential orchestrating role in creating a perfect immune balance, through a contradictory "immune paradox" profile that is only observed in pregnancy. The increase in TH2 cytokines coupled with binding to Treg cells may protect the embryo while the increase in TH1 cytokines under challenge may protect against infection. PIF expression shortly post-fertilization may reflect its dominant role in early pregnancy events. </p><p id="p0051" num="0051"> [0049] Embodiments described herein are directed to the use of PIF for the treatment of intracellular damage. Embodiments are directed to a method of treating intracellular damage comprising administering a PIF peptide to a subject in need thereof. In some embodiments, the PIF administered may increase cytokine secretion in response to intracellular damage. In some embodiments, PIF may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, the PIF administered is in a therapeutically effective amount. In some embodiments, a subject is diagnosed with intracellular damage. In some embodiments, the subject is at risk for intracellular damage. In some embodiments, the intracellular damage may be the result of a disease. In some embodiments, the disease is caused by an intracellular bacterium. In some 
<!-- EPO <DP n="17"/>-->
 embodiments, the intracellular bacterium may be selected from Listeria monocytogenes, Mycobacterium tuberculosis, Heliobacter pylori, Borrelia burgdorferi sensu stricto, Borelia afzelii, and Borrelia garinii. In further embodiments, the disease may be selected from Listeria, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis and tuberculosis. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. In some embodiments, the method may further comprise administering PIF in combination with other anti-intracellular damage agents. </p><p id="p0052" num="0052"> [0050] In embodiments of the present disclosure, methods of treating atherosclerosis in a subject comprising administering a PIF peptide are provided. In some embodiments, PIF may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, a therapeutically effective amount of PIF is administered. In some embodiments, a subject is diagnosed with atherosclerosis. In some embodiments, the subject is at risk for atherosclerosis. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active PIF peptide 
<!-- EPO <DP n="18"/>-->
 associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. In some embodiments, the method may further comprise administering PIF in combination with other anti-atherosclerotic agents. </p><p id="p0053" num="0053"> [0051] In some embodiments, PIF may treat atherosclerosis by reducing plaque in the aortic root. In some embodiments, PIF may treat atherosclerosis by reducing plaque in the aortic arch. In some embodiments, PIF may treat atherosclerosis by reducing a monocyte protein in the aortic arch. In further embodiments, the monocyte protein may be selected from vascular cell adhesion molecules (VCAM-1), monocyte chemotactic proteins (MCP-1) and clusters of differentiation (CD68). In some embodiments, PIF may treat atherosclerosis by reducing a monocyte protein in the aortic root. In further embodiments, the monocyte protein may be selected from vascular cell adhesion molecules (VCAM-1), monocyte chemotactic proteins (MCP-1) and clusters of differentiation (CD68). In some embodiments, PIF may treat atherosclerosis by reducing lipids in the aortic root. In some embodiments, PIF may treat atherosclerosis by reducing a cytokine in THP-1 cells. In further embodiments, the cytokine may be selected from interleukein 12, subunit beta (IL-12b) and interferon gamma (IFN-γ). The effect on plaque reduction on the aorta is direct without affecting circulating lipids. In embodiments, the level of circulating lipids is not substantially affected or otherwise substantially reduced. </p><p id="p0054" num="0054"> [0052] In embodiments of the present disclosure, methods of treating tuberculosis in a subject comprising administering a PIF peptide are provided. In some embodiments, methods of treating tuberculosis may comprise decreasing dissemination of Mycobacterium tuberculosis comprising administering a PIF peptide. In some embodiments, methods of treating tuberculosis may comprise increasing cytokine secretion in response to Mycobacterium tuberculosis infection comprising administering a PIF peptide. In some embodiments, the PIF peptide may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, a therapeutically effective amount 
<!-- EPO <DP n="19"/>-->
 of a PIF peptide is administered. In some embodiments, the subject is diagnosed with tuberculosis. In some embodiments, the subject is at risk for tuberculosis infection. In some embodiments, the subject has been exposed to Mycobacterium tuberculosis. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or, preferably, oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. In some embodiments, the method may further comprise administering PIF in combination with other anti-TB agents. </p><p id="p0055" num="0055"> [0053] In embodiments of the invention, methods of treating the symptoms of tuberculosis in a subject comprising administering a PIF peptide are provided. In such methods, the symptoms of tuberculosis may be selected from chest pain, cough, weight loss, energy loss, poor appetite, fever, night sweats, chills and combinations thereof. In some embodiments, the PIF peptide may be selected from SEQ ID NO: 1 ; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1 ; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, a therapeutically effective amount of a PIF peptide is administered. In some embodiments, the subject is diagnosed with tuberculosis. In some embodiments, the subject is at risk for tuberculosis infection. In some embodiments, the subject has been exposed to Mycobacterium tuberculosis. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are 
<!-- EPO <DP n="20"/>-->
 prepared in a manner well known in the art and comprise at least one active PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. In some embodiments, the method may further comprise administering PIF in combination with other anti-TB agents. </p><p id="p0056" num="0056"> [0054] In embodiments of the present disclosure, methods of treating peritonitis in a subject comprising administering a PIF peptide are provided. In some embodiments, PIF may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, a therapeutically effective amount of PIF is administered. In some embodiments, a subject is diagnosed with peritonitis. In some embodiments, the subject is at risk for peritonitis. In some embodiments, the PIF peptide is coadministered with a potassium channel inhibitor. In further embodiments the potassium channel inhibitor may be selected from IFNy, Kvl.3 inhibitor and combinations thereof. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. In some embodiments, the method may further comprise administering PIF in combination with other anti-atherosclerotic agents. 
<!-- EPO <DP n="21"/>-->
 [0055] Embodiments are directed to a method of upregulating B7-H1 comprising administering a PIF peptide to a subject in need thereof. In some embodiments, B7-H1 may positively control T-cell receptor-mediated signaling. In other embodiments, B7-H1 may negatively control T-cell receptor-mediated signaling. Some embodiments may be directed to methods of inhibiting a Kvl.3 channel comprising administering a PIF peptide to a subject in need thereof. Some embodiments may be directed to methods of inhibiting a Kvl .3 channel further comprising administering a Kvl .3 inhibitor to a subject in need thereof. In some embodiments, the administration of PIF peptide blocks the activity of the Kvl.3 potassium channel. In some embodiments, the PIF peptide blocks the activity of the Kvl .3 channel by binding to the channel. In some embodiments, the PIF peptide may be selected from SEQ ID NO: 1 ; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, a therapeutically effective amount of a PIF peptide is administered. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. </p><p id="p0057" num="0057"> [0056] Embodiments are directed to a method of treating inflammation from intracellular damage comprising administering a PIF peptide to a subject in need thereof. Some embodiments may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. Some embodiments may be directed to methods of increasing cytokine secretion in response to intracellular damage further comprising administering a Kvl.3 inhibitor to a subject in need 
<!-- EPO <DP n="22"/>-->
 thereof. In some embodiments, the PIF peptide may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1 ; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, a therapeutically effective amount of a PIF peptide is administered. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. </p><p id="p0058" num="0058"> [0057] In some aspects, a method of decreasing dissemination of tuberculosis bacteria comprising administering PIF to a subject in need thereof. In some embodiments, the PIF administered is in a therapeutically effective amount. In some embodiments, the PIF peptide may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or 
<!-- EPO <DP n="23"/>-->
 four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. </p><p id="p0059" num="0059"> [0058] Further embodiments are directed to the use of PIF to neutralize local immune suppression induced by Mtb-infected macrophages and/or increase host's immune response against Mtb infection. In some embodiments, the PIF peptide may be selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. In embodiments, the PIF peptide is selected from SEQ ID NO: 1 ; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4. In other embodiments, the PIF peptide is selected from SEQ ID NO: 1 ; SEQ ID NO: 2; SEQ ID NO: 3. In some embodiments, a therapeutically effective amount of a PIF peptide is administered. In some embodiments, the subject is diagnosed with tuberculosis. In some embodiments, the subject is at risk for tuberculosis infection. In some embodiments, the subject has been exposed to Mycobacterium tuberculosis. In some embodiments, the PIF peptide is administered in a pharmaceutical composition, wherein the pharmaceutical composition may comprise a therapeutically effective amount of a PIF peptide and a pharmaceutically acceptable excipient. In some embodiments, the PIF peptide is administered from a route selected from parenteral, transdermal, rectal, nasal, local intravenous administration, or oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active PIF peptide associated with a pharmaceutically carrier. In some embodiments, the PIF peptide is administered once a day, twice a day, three times a day or four times a day. In some embodiments, the PIF peptide is administered for one week, two weeks, three weeks, four weeks, two months, three months, four months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years or five years. In some embodiments, the method may further comprise administering PIF in combination with other anti-TB agents. Furthermore, PIF may prevent intracellular damage caused by tuberculosis. Whereas most conventional therapies act outside the cell rendering them ineffective to address intracellular damage, PIF acts within the cell and thereby may prevent immune cells from being taken hostage by invading intracellular bacteria, such as Mycobacterium tuberculosis. </p><p id="p0060" num="0060"> [0059] Glucocorticoids suppress the immune system, thus reducing inflammation and attendant pain and swelling at the site of the injury. A multi-protein complex composed 
<!-- EPO <DP n="24"/>-->
 of the unliganded glucocorticoid receptor ("GR"), Hsp90, and the tyrosine kinases LCK and FYN is recruited to the antigen activated T cell receptor (TCR) in T cells. This GR complex is necessary for TCR signaling. PIF in activated PBMC upregulates LCK, Fyn, and by reducing BAG3 expression HSP70, and 32 are activated. On binding of glucocorticoids to GR, this multi-protein complex dissociates blocking TCR signaling, thus suppressing the immune system. By binding to the T-cell receptor (TCR), PIF replaces cortisone and prevents immune suppression. Furthermore, by binding to the cortisone site, PIF reduces cortisone's side effects. Long-term cortisone exposure potentially has a number of severe side-effects including, but not limited to, hyperglycemia, insulin resistance, diabetes mellitus, osteoporosis, anxiety, depression, gastritis, colitis, hypertension, ictus, erectile dysfunction, hypogonadism, hypothyroidism, amenorrhoea, and retinopathy, among other problems. Accordingly, PIF affects Mtb-infected phagocytes, in particular the secretion of cytokines and chemokines, and prevents Mtb induced-immune suppression. Additionally, PIF binds to intracellular potassium channel KV1.3 beta (a sub-unit of a protein (Kvl.3)) which modulates major immune cell functions, controls potassium pore flux, and also binds to intracellular insulin degrading enzyme which may increase cytokine secretion in CD3/CD28-stimulated T- cells. Without wishing to be bound by theory, PIF may act as a treatment for TB in a similar way to clofazimine (anti-TB drug), which acts by binding the Kvl.3 channel. PIF also blocks NFAT 1 and the calcineurin pathways. Thus sPIF action may involve a direct antimacrobial effect acting within the infected macrophages. Thus, aspects of the invention are directed to the use of PIF for the treatment of tuberculosis. </p><p id="p0061" num="0061"> [0060] Due to its specific immune profile, PIF may be able to precisely enhance the immune response against Mtb within the granuloma, counteracting local immune suppression by acting synergistically to augment an anti-TB drug's effectiveness, reducing drug resistance, and the likelihood development of latent TB. Nowadays, to be effective, anti-TB therapy may need to be used for several months and in cases of resistant TB multiple drugs may be required. However, PIF may effectively activate the immune system against tuberculosis and latent tuberculosis (TB and LTB). Therefore, PIF may help in shortening the length of therapy and may even reduce the need for multiple drug use. Additionally, PIF may also address the other pathological aspects that generally occur (ex. organ damage) in connection with TB. Thus, in some embodiments, PIF may be administered in conjunction with other anti-TB agents. Such anti-TB agents may be selected from isoniazid, rifampin, ethambutol, pyrazinamide and combinations thereof. 
<!-- EPO <DP n="25"/>-->
 [0061] In some embodiments, PIF may be potentially used at all stages of intracellular damage: (1) early stages post-exposure where the immune system may be aided by PIF enabling immunity restoration; (2) later phase (if the attack was not timely caught) in which the disease or infection, such as, without limitation, TB, would have progressed and where PIF is expected to minimize the side-effects, allowing restoration of the immune system; and (3) latent infection, for example, in TB, where PIF may lower tuberculin-induced disease burden while maintaining body's fighting efficacy. </p><p id="p0062" num="0062"> [0062] As used herein, the terms "peptide," "polypeptide" and "protein" are used interchangeably and refer to two or more amino acids covalently linked by an amide bond or non-amide equivalent. The peptides of the invention can be of any length. For example, the peptides can have from about two to about 100 or more residues, such as, 5 to 12, 12 to 15, 15 to 18, 18 to 25, 25 to 50, 50 to 75, 75 to 100, or more in length. Preferably, peptides are from about 2 to about 18 residues. The peptides of the invention include 1- and d-isomers, and combinations of 1- and d-isomers. The peptides can include modifications typically associated with post-translational processing of proteins, for example, cyclization (e.g., disulfide or amide bond), phosphorylation, glycosylation, carboxylation, ubiquitination, myristylation, or lipidation. </p><p id="p0063" num="0063"> [0063] Peptides disclosed herein further include compounds having amino acid structural and functional analogues, for example, peptidomimetics having synthetic or non- natural amino acids or amino acid analogues, so long as the mimetic has one or more functions or activities of compounds of the invention. The compounds of the invention therefore include "mimetic" and "peptidomimetic" forms. </p><p id="p0064" num="0064"> [0064] The terms "mimetic," "peptide mimetic" and "peptidomimetic" are used interchangeably herein, and generally refer to a peptide, partial peptide or non-peptide molecule that mimics the tertiary binding structure or activity of a selected native peptide or protein functional domain (e.g., binding motif or active site). These peptide mimetics include recombinantly or chemically modified peptides, as well as non-peptide agents such as small molecule drug mimetics, as further described below. </p><p id="p0065" num="0065"> [0065] In some aspects, the invention is directed to a pharmaceutical composition comprising a PIF peptide, as defined above, and a pharmaceutically acceptable carrier or diluent, or an effective amount of a pharmaceutical composition comprising a compound as defined above. 
<!-- EPO <DP n="26"/>-->
 [0066] The compounds of the present invention can be administered in the conventional manner by any route where they are active. Administration can be systemic, topical, or oral. For example, administration can be, but is not limited to, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal, or ocular routes, or intravaginally, by inhalation, by depot injections, or by implants. Thus, modes of administration for the compounds of the present invention (either alone or in combination with other pharmaceuticals) can be, but are not limited to, sublingual, injectable (including short-acting, depot, implant and pellet forms injected subcutaneously or intramuscularly), or by use of vaginal creams, suppositories, pessaries, vaginal rings, rectal suppositories, intrauterine devices, and transdermal forms such as patches and creams. </p><p id="p0066" num="0066"> [0067] Specific modes of administration will depend on the indication. The selection of the specific route of administration and the dose regimen is to be adjusted or titrated by the clinician according to methods known to the clinician in order to obtain the optimal clinical response. The amount of compound to be administered is that amount which is therapeutically effective. The dosage to be administered will depend on the characteristics of the subject being treated, e.g., the particular animal treated, age, weight, health, types of concurrent treatment, if any, and frequency of treatments, and can be easily determined by one of skill in the art (e.g., by the clinician). </p><p id="p0067" num="0067"> [0068] Pharmaceutical formulations containing the therapeutic of the present invention and a suitable carrier can be solid dosage forms which include, but are not limited to, tablets, capsules, cachets, pellets, pills, powders and granules; topical dosage forms which include, but are not limited to, solutions, powders, fluid emulsions, fluid suspensions, semisolids, ointments, pastes, creams, gels and jellies, and foams; and parenteral dosage forms which include, but are not limited to, solutions, suspensions, emulsions, and dry powder; comprising an effective amount of a polymer or copolymer of the present invention. It is also known in the art that the active ingredients can be contained in such formulations with pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like. The means and methods for administration are known in the art and an artisan can refer to various pharmacologic references for guidance. For example, Modern Pharmaceutics, Banker &amp; Rhodes, Marcel Dekker, Inc. (1979); and Goodman &amp; Gilman's The Pharmaceutical Basis of Therapeutics, 6th Edition, MacMillan Publishing Co., New York (1980) can be consulted. 
<!-- EPO <DP n="27"/>-->
 [0069] The compounds of the present invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. The compounds can be administered by continuous infusion subcutaneously over a period of about 15 minutes to about 24 hours. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. </p><p id="p0068" num="0068"> [0070] For oral administration, the compounds can be formulated readily by combining these compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, but are not limited to, fillers such as sugars, including, but not limited to, lactose, sucrose, mannitol, and sorbitol; cellulose preparations such as, but not limited to, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone (PVP). If desired, disintegrating agents can be added, such as, but not limited to, the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. </p><p id="p0069" num="0069"> [0071] Dragee cores can be provided with suitable coatings. For this purpose, concentrated sugar solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. </p><p id="p0070" num="0070"> [0072] Pharmaceutical preparations which can be used orally include, but are not limited to, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as, e.g., lactose, binders such as, e.g., starches, and/or lubricants such as, e.g., talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as 
<!-- EPO <DP n="28"/>-->
 fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers can be added. All formulations for oral administration should be in dosages suitable for such administration. </p><p id="p0071" num="0071"> [0073] For buccal administration, the compositions can take the form of, e.g., tablets or lozenges formulated in a conventional manner. </p><p id="p0072" num="0072"> [0074] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. </p><p id="p0073" num="0073"> [0075] The compounds of the present invention can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. </p><p id="p0074" num="0074"> [0076] In addition to the formulations described previously, the compounds of the present invention can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. </p><p id="p0075" num="0075"> [0077] Depot injections can be administered at about 1 to about 6 months or longer intervals. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. </p><p id="p0076" num="0076"> [0078] In transdermal administration, the compounds of the present invention, for example, can be applied to a plaster, or can be applied by transdermal, therapeutic systems that are consequently supplied to the organism. </p><p id="p0077" num="0077"> [0079] Pharmaceutical compositions of the compounds also can comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as, e.g., polyethylene glycols. </p><p id="p0078" num="0078"> [0080] The compounds of the present invention can also be administered in combination with other active ingredients, such as, for example, adjuvants, protease 
<!-- EPO <DP n="29"/>-->
 inhibitors, or other compatible drugs or compounds where such combination is seen to be desirable or advantageous in achieving the desired effects of the methods described herein. </p><p id="p0079" num="0079"> [0081] In some embodiments, the disintegrant component comprises one or more of croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, an ion exchange resin, an effervescent system based on food acids and an alkaline carbonate component, clay, talc, starch, pregelatinized starch, sodium starch glycolate, cellulose floe, carboxymethylcellulose, hydroxypropylcellulose, calcium silicate, a metal carbonate, sodium bicarbonate, calcium citrate, or calcium phosphate. </p><p id="p0080" num="0080"> [0082] In some embodiments, the diluent component comprises one or more of mannitol, lactose, sucrose, maltodextrin, sorbitol, xylitol, powdered cellulose, microcrystalline cellulose, carboxymethylcellulose, carboxyethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose, starch, sodium starch glycolate, pregelatinized starch, a calcium phosphate, a metal carbonate, a metal oxide, or a metal aluminosilicate. </p><p id="p0081" num="0081"> [0083] In some embodiments, the optional lubricant component, when present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, silica, silicic acid, talc, propylene glycol fatty acid ester, polyethoxylated castor oil, polyethylene glycol, polypropylene glycol, polyalkylene glycol, polyoxyethylene-glycerol fatty ester, polyoxyethylene fatty alcohol ether, polyethoxylated sterol, polyethoxylated castor oil, polyethoxylated vegetable oil, or sodium chloride. </p><p id="p0082" num="0082"> [0084] In one embodiment, the PIF peptides of the invention are modified to produce peptide mimetics by replacement of one or more naturally occurring side chains of the 20 genetically encoded amino acids (or D amino acids) with other side chains, for instance with groups such as alkyl, lower alkyl, cyclic 4-, 5-, 6-, to 7 membered alkyl, amide, amide lower alkyl, amide di (lower alkyl), lower alkoxy, hydroxy, carboxy and the lower ester derivatives thereof, and with 4-, 5-, 6-, to 7 membered heterocyclics. For example, proline analogs can be made in which the ring size of the proline residue is changed from 5 members to 4, 6, or 7 members. Cyclic groups can be saturated or unsaturated, and if unsaturated, can be aromatic or nonaromatic. Heterocyclic groups can contain one or more nitrogen, oxygen, and/or sulphur heteroatoms. Examples of such groups include the furazanyl, furyl, imidazolidinyl, imidazolyl, imidazolinyl, isothiazolyl, isoxazolyl, 
<!-- EPO <DP n="30"/>-->
 morpholinyl (e.g. morpholino), oxazolyl, piperazinyl (e.g. 1-piperazinyl), piperidyl (e.g. 1- piperidyl, piperidino), pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl (e.g. 1 -pyrrolidinyl), pyrrolinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, thiomorpholinyl (e.g. thiomorpholino), and triazolyl. These heterocyclic groups can be substituted or unsubstituted. Where a group is substituted, the substituent can be alkyl, alkoxy, halogen, oxygen, or substituted or unsubstituted phenyl. Peptidomimetics may also have amino acid residues that have been chemically modified by phosphorylation, sulfonation, biotinylation, or the addition or removal of other moieties. </p><p id="p0083" num="0083"> [0085] A variety of techniques are available for constructing peptide mimetics with the same or similar desired biological activity as the corresponding native but with more favorable activity than the peptide with respect to solubility, stability, and/or susceptibility to hydrolysis or proteolysis (see, e.g., Morgan &amp; Gainor, Ann. Rep. Med. Chem. 24,243- 252,1989). Certain peptidomimetic compounds are based upon the amino acid sequence of the peptides of the invention. Often, peptidomimetic compounds are synthetic compounds having a three-dimensional structure (i.e. a "peptide motif) based upon the three- dimensional structure of a selected peptide. The peptide motif provides the peptidomimetic compound with the desired biological activity, i.e., binding to PIF receptors, wherein the binding activity of the mimetic compound is not substantially reduced, and is often the same as or greater than the activity of the native peptide on which the mimetic is modeled. Peptidomimetic compounds can have additional characteristics that enhance their therapeutic application, such as increased cell permeability, greater affinity and/or avidity and prolonged biological half-life. </p><p id="p0084" num="0084"> [0086] Peptidomimetic design strategies are readily available in the art (see, e.g., Ripka &amp; Rich, Curr. Op. Chem. Biol. 2,441-452, 1998; Hruby et al., Curr. Op.Chem. Biol. 1,114-1 19,1997; Hruby &amp; Balse, Curr. Med. Chem. 9,945-970, 2000). One class of peptidomimetics a backbone that is partially or completely non-peptide, but mimics the peptide backbone atom-for atom and comprises side groups that likewise mimic the functionality of the side groups of the native amino acid residues. Several types of chemical bonds, e.g., ester, thioester, thioamide, retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, are known in the art to be generally useful substitutes for peptide bonds in the construction of protease-resistant peptidomimetics. Another class of peptidomimetics comprises a small non-peptide molecule that binds to another peptide or protein, but which is not necessarily a structural mimetic of the native peptide. Yet another 
<!-- EPO <DP n="31"/>-->
 class of peptidomimetics has arisen from combinatorial chemistry and the generation of massive chemical libraries. These generally comprise novel templates which, though structurally unrelated to the native peptide, possess necessary functional groups positioned on a nonpeptide scaffold to serve as "topographical" mimetics of the original peptide (Ripka &amp; Rich, 1998, supra). </p><p id="p0085" num="0085"> [0087] Embodiments and methods of the present invention may use any of the following PIF peptides: Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala (SEQ ID NO: 1); Met-Val- Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser (SEQ ID NO: 2); Met-Val-Arg-Ile-Lys-Pro- GlySer-Ala-Asn-Lys-Pro-Ser-Asp-Asp (SEQ ID NO: 3); Met-Val-Arg-Ile-Lys-Tyr-Gly-Ser- Tyr-Asn-Lys-Pro-Ser-Asp (SEQ ID NO: 4); Ser-Gly-Ile-Val-Ile-Tyr-Gln-Tyr-Met-Asp-Asp- Arg-Tyr-Val-Gly-Ser-Asp-Leu (SEQ ID NO: 5); Val-Ile-Ile-Ile-Ala-Gln-Tyr-Met-Asp (SEQ ID NO: 6); Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr (SEQ ID NO: 7); Ser-Gln-Ala-Val- Gln-Glu-His-Ala-Ser-Thr-Asn-Xaa-Gly, where Xaa can be any amino acid (SEQ ID NO: 8). </p><p id="p0086" num="0086"> [0088] A list of PIF peptides, both the isolated, natural and synthetic, are provided below in Table 1. Antibodies to various PIF peptides and scrambled PIF peptides are also provided. </p><p id="p0087" num="0087">Table 1. PIF Peptides </p><p id="p0088" num="0088">(SEQ ID NO) Peptide Amino Acid Sequence </p><p id="p0089" num="0089"> (isolated, natural or synthetic)</p><p id="p0090" num="0090">SEQ ID NO: 1 PIF-1(9) MVRIKPGSA isolated native, matches region of </p><p id="p0091" num="0091">Circumsporozoite protein (Malaria) </p><p id="p0092" num="0092"> SEQ ID NO: 2 PIF- l( i 3) MVRIKPGSANKPS isolated native, matches region of </p><p id="p0093" num="0093">Circumsporozoite protein (Malaria) </p><p id="p0094" num="0094"> SEQ ID NO: 3 PIF-1<sub>(15)</sub> MVRI PGSANKPSDD isolated native, matches region of </p><p id="p0095" num="0095">Circumsporozoite protein (Malaria) 
<!-- EPO <DP n="32"/>-->
 SEQ ID NO: 4 PIF-l(i4) MVRIKYGSYNKPSD isolated native, matches region of </p><p id="p0096" num="0096">Circumsporozoite protein (Malaria) </p><p id="p0097" num="0097"> SEQ ID NO: 5 PIF-3<sub>(18)</sub> SGIVIYQYMDDRYVGSDL isolated native, matches region of Rev </p><p id="p0098" num="0098">Trans </p><p id="p0099" num="0099"> SEQ ID NO:6 PIF-4(9) VIIIAQYMD </p><p id="p0100" num="0100"> SEQ ID NO: 7 PIF-2<sub>(10)</sub> SQAVQEHAST isolated native, matches region of human </p><p id="p0101" num="0101">retinoid and thyroid hormone receptor- SMRT</p><p id="p0102" num="0102">SEQ ID NO: 8 PIF-2<sub>(13)</sub> SQAVQEHASTNXG isolated native, matches region of human </p><p id="p0103" num="0103">retinoid and thyroid hormone receptor- SMRT </p><p id="p0104" num="0104">( )= number of AA </p><p id="p0105" num="0105">[0089] This invention and embodiments illustrating the method and materials used may be further understood by reference to the following non-limiting examples. </p><p id="p0106" num="0106">EXAMPLE 1 </p><p id="p0107" num="0107">[0090] Peptide synthesis: Synthetic PIF- I 15 (MVRIKPGSANKPSDD) was obtained by solid-phase peptide synthesis (Peptide Synthesizer, Applied Biosystems) employing Fmoc (9-fluorenylmethoxycarbonyl) chemistry. Final purification is carried out by reverse-phase HPLC and identity is verified by MALDI-TOF mass spectrometry and amino acid analysis and purified to &gt;95%, by HPLC, and documented by mass spectrometry (Biosynthesis, Texas). 
<!-- EPO <DP n="33"/>-->
 EXAMPLE 2 </p><p id="p0108" num="0108">[0091] As shown in FIG. 4, cultured bone marrow derived phagocytes were exposed to PIF (SEQ ID NO. 4; peptide MVRIKPGSANKPSDD), interferon-gamma (phagocyte-activating cytokine) and Mtb and measured the cytokine response in the presence or absence of Kvl.3, a potassium channel inhibitor. MCP-1 (a chemokine) interleukin (IL)-6 and IL-5 were increased by Mtb; this induction was augmented by PIF and blocked by Kvl.3 inhibition. MIG and IP 10 chemokines were modestly augmented by PIF when IFN activated phagocytes were exposed to Mtb; inhibition of Kvl.3 reduced the PIF effect. PIF augmented VEGF and FGFp induction by Mtb (regardless of phagocyte activation by IFNy) and inhibition of Kvl.3 augmented this response. Inflammatory cytokines TNF, IL-la, IL-Ιβ, MlPla and KC were induced by Mtb, augmented by PIF and further augmented by anti Kvl.3. In conclusion, PIF-conditioned macrophages exhibit an altered response to Mtb. PIF was able to modulate the phagocyte response to Mtb and may therefore modulate disease development </p><p id="p0109" num="0109">EXAMPLE 3 </p><p id="p0110" num="0110">[0092] sPIF effectively controls Mtb-infected macrophages: In vitro studies used mouse bone marrow derived dendritic cells (BMDCs) exposed to Mtb +/-PIF for 24 hrs in culture. sPIF clearly modulated the phagocyte response to Mtb at low (nM) physiological PIF concentrations. Pre-treatment with sPIF resulted in BMDCs augmented response to Mtb specifically: inflammatory cytokines TNF, IL-la, IL-lb and IL-6 and chemokines MCP-1 MlPla and KC were increased. Importantly, sPIF acted to increase the response of BMDC even in absence of pre-activation by interferon-γ. VEGF and FGFb (growth factors) were also augmented by sPIF suggesting its capability to modulate the remodeling activity of BMDCs. Hence, PIF exerts a potent anti-mycobacterial response that is evidenced both in absence and presence of acquired immunity as represented by interferon-γ pre-treatment. </p><p id="p0111" num="0111"> [0093] Whether binding to Kvl.3b is also relevant in the BMDC context was demonstrated by using an anti-Kvl.3 inhibitor. A number of sPIF induced cytokine and chemokine secretion patterns were modified in the presence of the inhibitor. Collectively the in vitro and in vivo data (BMDC Mtb data) support the sPIF's efficacy to control Mtb infection. 
<!-- EPO <DP n="34"/>-->
 EXAMPLE 4 </p><p id="p0112" num="0112">[0094] As shown in FIGS. 4 and 5, the objective of this study was to assess the ability of PIF to (1) modulate Mtb infected cultured phagocytes; and (2) control chronic acquired Mtb infection in a murine model. Results indicated that PIF modulates cytokine/chemokine secretion. MCP1, IL6, and IL5, were increased by Mtb, further induced by PIF, and blocked by Kvl.3 inhibitor. MIG, and IP 10 were modestly augmented by PIF when IFNy was added to Mtb, Kvl .3 inhibitor blocked effect. PIF promoted VEGF, and FGF induction by Mtb (regardless of IFNy activation); and the Kvl .3 inhibitor augmented this effect. TNFa, IL-la, IL-lb, MlPla, and KC were induced by Mtb, is augmented by PIF, and further augmented by Kvl.3 inhibitor. Mice were infected via aerosol with 75 cfu Mtb at day 0. Infected mice were then treated with 0.1 mg/kg PIF daily injection at day 60-70, followed by 10 day observation. Viable Mtb bacteria count of lung tissue was assessed on day 80, 10 days post-therapy. In vivo, short-term, low-dose PIF treatment reduced Mtb infection. This effect persisted 10 day post-therapy (see FIG. 5). </p><p id="p0113" num="0113"> [0095] In conclusion, PIF treated phagocytes exhibited an altered response to Mtb. PIF modulated Mtb infected phagocytes cytokine/chemokine secretion in a response which was partially Kvl.3 dependent. PIF had a therapeutic effect on chronically Mtb-infected mice. PIF Rx was low-dose, short-term and achieved long-term effects persisting after the end of PIF administration (0.1 mg, 10 day, 10-80 day post-therapy). </p><p id="p0114" num="0114">EXAMPLE 5 </p><p id="p0115" num="0115">[0096] Two inhibitors were tested for an effect on PIF modulation of cytokine production by stimulated human T lymphocytes. Peripheral blood was obtained from two healthy donors. Mononuclear cells were purified by Ficol-Hypaque centrifugation. Cultures were prepared in duplicate wells at 8 x 10<sup>4</sup> cells per well having either (1) Media with 0, 1, 10 and 50nM PIF; (2) anti-CD3/CD28 stimulation without and with Kvl.3 inhibitor at ΙΟΟηΜ, IDE inhibitor at 5μΜ, or both together or (3) anti-CD3/CD28 stimulation without and with Kvl .3 inhibitor at lOOnM, IDE inhibitor at 5μΜ, or both together with 1, 10 or 50nM PIF. The culture supernatants were collected 24 hours post-treatment and were assayed for eleven Thl/Th2 cytokines using a multiplex system (Bender, Cat. No. BMS810FF): IL-lbeta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-alpha, TNF-beta, IFN-gamma. 
<!-- EPO <DP n="35"/>-->
 [0097] As shown in FIG. 3, results indicated that PIF alone tested at 1, 10 and 50nM had no effect on the multiple analytes tested. CD3/CD28 did not activate the production of IL-12, IL-4, IL-5, IL-lb and TNFp. Without CD3/CD28 induction, the level of IL-8 is very high (over the Upper limit of Quantification -8.91 ng/mL)). It appears that CD3/CD28 down-regulates the IL-8 production. A significant effect of PIF or Kvl.3 inhibitor, or IDE inhibitor, was not clear. CD3/CD28 T-cell stimulation induced secretion of IFNg, IL-2, 11-6 and TNFa. A slightly higher induction with the donor 2 cells was observed. In the presence of PIF at 1, 10 and 50 nM, the analytes' level was reduced in the presence of 5μΜ IDE inhibitor, but not in the presence of lOOnM Kvl .3 inhibitor. There was a decrease in the presence of both inhibitors. </p><p id="p0116" num="0116"> [0098] In conclusion, PIF was shown to bind intracellular insulin degrading enzyme (IDE) in a cell based assay using specific IDE inhibitor. </p><p id="p0117" num="0117">EXAMPLE 6 </p><p id="p0118" num="0118">[0099] PIF antipathogenic effect is further documented on PBMC mRNA modulating TOLL receptors among many other genes. The embryo/allograft is a perfect transplant, tolerated by mother/host, while preserving her defense mechanisms to fight disease. Preimplantation factor (PIF) is necessary for viable pregnancy, orchestrating implantation, possibly modulating maternal immunity favoring acceptance. </p><p id="p0119" num="0119"> [00100] As shown in FIG. 1, sPIF (PIF analog) was tested on naive and TCR-co- activated human PBMCs assessing proliferation, cytokine secretion and mRNA expression. FITC-sPIF binding to PBMCs subsets was determined using flow cytometry. sPIF's effect on Ca++ mobilization was tested by Flex station. PIF was detected within pregnant mouse uterus using anti-PIF-monoclonal antibody. sPIF was found to modulate PBMCs: blocked anti-CD3-Mab-stimulated proliferation and mixed lymphocyte reaction. In na<sup>'</sup>ive-PBMCs, sPIF reduces TH1 (TNF-a, IL2) cytokines while in activated PBMCs. sPIF promotes TH2 (IL-10, IL4, IL5, IL3), and TH1 (IL2, IFNy) cytokines. Co-stimulation led to TH2/TH1 cytokine bias and global gene analysis demonstrated an increased pro-tolerant and reduced pro-inflammatory profile. FITC-sPIF binds all CD 14+, and activated T cells, key regulatory FOXP3+ Tregs (Treg) and B cells. PIF does not act through Ca++ mobilization, a common pathway for immune suppressive agents. PIF is preferentially taken up by uterine NK cells in pregnant murine uterus. 
<!-- EPO <DP n="36"/>-->
 [00101] In conclusion, the post-fertilization embryo, through its comprehensive 1 PIF-based signaling, modulates peripheral immunity to create tolerance without immune suppression. Under challenged conditions, PIF promotes maternal ability to fight disease. Through control of NK cells, PIF may reduce maternal rejection towards the embryo within the uterus. Overall, PIF plays a fundamental role in the implantation process, orchestrating maternal recognition of pregnancy, and controlling both peripheral and local immune environments. PIF binds CD14+ cells and at elevated concentrations to T and B 580 cells. Unstimulated PBMC were cultured for 24 hours, and the binding of FITC-PIF 581 (0.3-25 μg/ml) to specific PBMC sub-populations was determined using surface markers 582 by flow cytometry with two-color stain or microscopy. FIG. 1 shows FITC-PIF presence inside the cell. </p><p id="p0120" num="0120">EXAMPLE 7 </p><p id="p0121" num="0121">[00102] As shown in FIG. 2, cells (200,000/well) were stimulated with plate-bound anti-CD3 antibody or anti-CD3/anti-CD28 MAb 10μg/ml or by heterologous mixed lymphocyte reaction (MLR), cultured 2-4 days in serum-free medium (GIBCO™ AIM-V Medium, Invitrogen Corp., Carlsbad, CA) containing 0-500nM sPIF or PIFscr. In some experiments, IL2r recombinant (30 U/ml) +/- sPIF was added. Proliferation was determined by [3H]-thymidine incorporation. In other experiments, sPIFO-ΙΟΟΟηΜ tested on isolated T- cells (CD3+) on both MLR and anti-CD3/anti-CD28 MAbK^g ml stimulated-PBMCs. </p><p id="p0122" num="0122">EXAMPLE 8 </p><p id="p0123" num="0123">[00103] Invitrogen's Protein-Protein Interaction Profiling Service was performed on ProtoArray® Human Protein Microarrays v5.0 and the interaction with more than 9,000 human proteins was investigated. One Alexa Fluor® 647-conjugated synthetic peptide, provided by the CAR! Reproductive Institute, designated as PIF-Alexa 647, was used to probe the microarrays at two concentrations (250 nM and 2.5 μΜ) in duplicate. The results from these assays were compared to a negative control assay in which the probe protein was excluded. All interactions of the probe protein with the immobilized proteins on the microarrays were evaluated by specified statistical threshold criteria within the array and compared to interactions observed on the negative control array. Visual confirmation of the positive hits was also performed by directly inspecting the array images to verify the 
<!-- EPO <DP n="37"/>-->
 authenticity and quality of the signals. From these analyses, a total of eleven (11) human proteins were identified as candidate interactors for PIF-Alexa 647. </p><p id="p0124" num="0124">EXAMPLE 9 </p><p id="p0125" num="0125">[00104] To demonstrate the therapeutic potential of PIF, male ApoE-/- mice were fed a high fat Western diet containing 22% fat and 0.15% cholesterol for 7 weeks. Mice were then randomly assigned to one of six clusters; 3 intervention groups of varied PIF doses, and 3 control groups of scrPIF or PBS. Treatments were administered via 150μΕ i.p. injection every 3rd day, for a total of 7 weeks. </p><p id="p0126" num="0126"> [00105] As shown in FIG. 7, PIF O.lmg/kg/day treatment significantly reduced the plaque area in the aortic root by 30% compared to the PBS control (D, **p=0.0008). A greater reduction of 46% was evident in PIF lmg/kg/day compared to PBS (D, ****p&lt;0.0001). The higher dose of PIF also statistically significantly reduced plaque area compared to both doses of scrPIF (****p&lt;0.0001). PIF lmg/kg/day treatment significantly reduced the plaque area of the aortic arch by 43% compared to the PBS control (E, **p&lt;0.002). A reduction was again also evident between PIF lmg/kg/day and both doses of scrPIF (***p=0.0005, **** p&lt; 0.0001 respectively). Furthermore, as shown in FIGS. 8-10, PIF also reduced VCAM-1, MCP-1, CD68 and lipids in the aortic root and arch. </p><p id="p0127" num="0127"> [00106] In conclusion, PIF reduces atherosclerosis formation in a mouse model that is prone to the disease and is fed a high fat diet. The protection was direct and led to reduced atherosclerotic plaques on both the aortic arch and root-target sites. A decrease in fat accumulation was evident, as well as a decrease in inflammatory macrophages and a lower number of fat foam cells. The protective effect was not related to changes in circulating lipids, as their levels did not change following PIF administration (see FIG. 11). The effect was specific since it was not replicated by PIFscr and PBS. PIF offers a new safe and targeted treatment for protection against atherosclerosis, which is a major health disorder mainly in the developed world. </p><p id="p0128" num="0128">EXAMPLE 10 </p><p id="p0129" num="0129"> [00107] To demonstrate that PIF inhibits MCP-1 induced monocyte migration, a mouse peritonitis model study was conducted. In this model, 8-12 weeks old C57bl6 mice were injected with either PIF, scPIF (0.3nmol/g i.p.) or PBS as a vehicle control. Peritonitis was induced by injecting 3ml 4% thioglycolate i.p. and after 20 hours, the mice were 
<!-- EPO <DP n="38"/>-->
 anaesthetized and the peritoneal cavity was flushed with 5ml sterile PBS. Subsequently, monocytes and macrophages were quantified with F4/80 and CD1 lb in flow cytometry. </p><p id="p0130" num="0130"> [00108] As shown in FIG. 6, the results showed that PIF (ΙμΜ &amp; 10μΜ) significantly reduced MCP-1 induced transmigration of THP-1 cells in an in vitro transwell migration assay (*p&lt;0.01). PIF further inhibited leukocyte adhesion and rolling in mesenteric venules in intravital microscopy using the peritonitis model as described in and cell staining with rhodamine. </p><p id="p0131" num="0131">EXAMPLE 11 </p><p id="p0132" num="0132"> [00109] Healthy pregnancy requires coordination of several soluble factors acting individually or in synergy with each other. Examples of those soluble factors include HLA- G, cytokines, and progesterone. The soluble factors are secreted during infection, which affects fetal development and often causes complications which may result in abortive pregnancy. PIF exerts an autocrine trophic protective effect on the embryo and promotes embryo implantation and trophoblast invasion. A determination was made as to whether PIF affects LPS-induced nitrous oxide (NO) secretion by macrophages and how PIF limits macrophage responses to LPS, which is the major endotoxin of gram negative bacteria. </p><p id="p0133" num="0133"> [00110] A macrophage cell line was cultured with 200nM PIF (synthetic PIF analog) for 2 and 5 days. In the last 24 hours of the experiment, LPS was added to the culture for cell activation. A Greiss reagent test was performed to detect NO secretion to the supernatant. Surface Plasmon Resonance spectroscopy (SPR) was used to evaluate LPS and LPS receptors binding (TLR4-MD2 and CD 14) to the PIF-labeled sensor surface. Two chemotypes of LPS (From E.coli 055:B5 and E.coli EH100) at 3 concentrations (5, 25 and 100 μΜ) were tested. </p><p id="p0134" num="0134"> [00111] The results showed that PIF 200 nM did not affect the baseline NO at either the 2 or the 5 day incubation. In contrast, PIF significantly down-regulated NO production following LPS activation. The effect at 2 days was more pronounced than at 5 days (P&lt;0.05). Preliminary results indicated an apparent absence of binding of immobilized PIF to both LPS chemotypes tested; similarly, no binding was observed to the scrambled PIF used as the control (random peptide of same amino acid in random order). To ascertain PIF's structural integrity, a PIF-specific antibody was incubated with purified PIF and results showed that the antibody bound to PIF. Under the conditions set up for the SPR analysis, PIF exhibited no apparent LPS binding. 
<!-- EPO <DP n="39"/>-->
 [00112] In conclusion, PIF was shown to block NO secretion, a major LPS-induced reactive nitrogen intermediate produced by iNOS, which is an enzyme absent in resting macrophages. PIF does not bind directly LPS, but its action might involve binding to LPS- associated receptors such as CD14, MD2 and macrophage scavenger receptor (SR). Such data supports a targeted anti-inflammatory effect of PIF on the innate immune system. 
</p></description><claims mxw-id="PCLM44851201" ref-ucid="WO-2012119072-A2" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="40"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A method of treating intracellular damage comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; or SEQ ID NO: 8. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The method of claim 1 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The method of claim 3, wherein the potassium channel inhibitor is a Kvl.3 inhibitor. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The method of claim 3, wherein the potassium channel inhibitor is IFNy. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The method of claim 1, wherein the intracellular damage is the result of a disease selected from Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis or tuberculosis. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The method of claim 1, wherein the treating further comprises increasing cytokine secretion in response to the intracellular damage. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. A method of treating intracellular infection comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; or SEQ ID NO: 8. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The method of claim 7 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The method of claim 8, wherein the potassium channel inhibitor is a Kvl.3 inhibitor. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The method of claim 8, wherein the potassium channel inhibitor is IFNy. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>11. The method of claim 7, wherein the intracellular infection is selected from Listeria monocytogenes, Mycobacterium tuberculosis, Heliobacter pylori, Borrelia burgdorferi sensu stricto, Borelia afzelii, and Borrelia garinii. <!-- EPO <DP n="41"/>--> </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. A method of modulating a potassium channel comprising administering a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The method of claim 12, wherein the potassium channel is a Kvl.3 channel. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The method of claim 12 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The method of claim 14, wherein the potassium channel inhibitor is a Kvl.3 inhibitor. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. The method of claim 14, wherein the potassium channel inhibitor is IFNy. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. A method of treating tuberculosis comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; or SEQ ID NO: 8. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. The method of claim 17 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. The method of claim 18, wherein the potassium channel inhibitor is a Kvl .3 inhibitor. </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. The method of claim 18, wherein the potassium channel inhibitor is IFNy. </claim-text></claim><claim id="clm-0021" num="21"><claim-text>21. The method of claim 17, wherein the tuberculosis may be a result of a mycobacterium tuberculosis infection. </claim-text></claim><claim id="clm-0022" num="22"><claim-text>22. The method of claim 17, wherein the treating comprises increasing cytokine secretion in response to a mycobacterium tuberculosis infection. </claim-text></claim><claim id="clm-0023" num="23"><claim-text>23. A method of decreasing dissemination of tuberculosis bacteria comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8. <!-- EPO <DP n="42"/>--> </claim-text></claim><claim id="clm-0024" num="24"><claim-text>24. The method of claim 23 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0025" num="25"><claim-text>25. The method of claim 24, wherein the potassium channel inhibitor is a Kvl.3 inhibitor. </claim-text></claim><claim id="clm-0026" num="26"><claim-text>26. The method of claim 24, wherein the potassium channel inhibitor is IFNy. </claim-text></claim><claim id="clm-0027" num="27"><claim-text>27. A method of treating atherosclerosis comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; or SEQ ID NO: 8. </claim-text></claim><claim id="clm-0028" num="28"><claim-text>28. The method of claim 27 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0029" num="29"><claim-text>29. The method of claim 28, wherein the potassium channel inhibitor is a Kvl .3 inhibitor. </claim-text></claim><claim id="clm-0030" num="30"><claim-text>30. The method of claim 28, wherein the potassium channel inhibitor is IFNy. </claim-text></claim><claim id="clm-0031" num="31"><claim-text>31. The method of claim 27, wherein the treating comprises reducing plaque, reducing monocyte proteins, reducing lipids, reducing cytokines and combinations thereof. </claim-text></claim><claim id="clm-0032" num="32"><claim-text>32. The method of claim 31 , wherein the reducing is completed in an aortic arch, an aortic root and combinations thereof. </claim-text></claim><claim id="clm-0033" num="33"><claim-text>33. The method of claim 31, wherein the monocyte proteins may be selected from one or more of vascular cell adhesion molecules, monocyte chemotactic proteins and clusters of differentiation. </claim-text></claim><claim id="clm-0034" num="34"><claim-text>34. The method of claim 31 , wherein the cytokines may be selected from one or more of interleukein 12, subunit beta, and interferon gamma. </claim-text></claim><claim id="clm-0035" num="35"><claim-text>35. The method of claim 31, wherein the level of circulating lipids is not substantially affected. <!-- EPO <DP n="43"/>--> </claim-text></claim><claim id="clm-0036" num="36"><claim-text>36. A method of reducing lipids comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; or SEQ ID NO: 8. </claim-text></claim><claim id="clm-0037" num="37"><claim-text>37. The method of claim 36 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0038" num="38"><claim-text>38. The method of claim 37, wherein the potassium channel inhibitor is a Kvl.3 inhibitor. </claim-text></claim><claim id="clm-0039" num="39"><claim-text>39. The method of claim 37, wherein the potassium channel inhibitor is IFNy. </claim-text></claim><claim id="clm-0040" num="40"><claim-text>40. The method of claim 36, wherein the treating comprises reducing plaque, reducing monocyte proteins, reducing lipids, reducing cytokines and combinations thereof. </claim-text></claim><claim id="clm-0041" num="41"><claim-text>41. The method of claim 40, wherein the reducing is completed in an aortic arch, an aortic root and combinations thereof. </claim-text></claim><claim id="clm-0042" num="42"><claim-text>42. The method of claim 40, wherein the monocyte proteins may be selected from one or more of vascular cell adhesion molecules, monocyte chemotactic proteins and clusters of differentiation. </claim-text></claim><claim id="clm-0043" num="43"><claim-text>43. The method of claim 40, wherein the cytokines may be selected from one or more of interleukein 12, subunit beta and interferon gamma. </claim-text></claim><claim id="clm-0044" num="44"><claim-text>44. A method of treating peritonitis comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; or SEQ ID NO: 8. </claim-text></claim><claim id="clm-0045" num="45"><claim-text>45. The method of claim 44 further comprising administering a potassium channel inhibitor. </claim-text></claim><claim id="clm-0046" num="46"><claim-text>46. The method of claim 45, wherein the potassium channel inhibitor is a Kvl .3 inhibitor. </claim-text></claim><claim id="clm-0047" num="47"><claim-text>47. The method of claim 45, wherein the potassium channel inhibitor is IFNy. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
